Replies to post #347449 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Shall we quibble over dosages, or efficacies?

Imo it is far too early to pontificate and/or quibble based on one pre-clinical murine paper on A3-71 so far out into the future, while the focus needs to be on getting revenue from A2-73.

I do feel uneasy, based on experience, when I see a biotech taking on lots of funding and starting on a new pipeline drug just before an important readout.

Hoping that the AVATAR readout is absolutely great and then in due course to dive into and pontificate deeper on A3-71 with much more excitement.